Literature DB >> 18690117

Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers.

Kenneth A Perkins1, Caryn Lerman, Sarah Coddington, Christopher Jetton, Joshua L Karelitz, Annette Wilson, J Richard Jennings, Robert Ferrell, Andrew W Bergen, Neal L Benowitz.   

Abstract

Genetic variation may influence initial sensitivity to nicotine (i.e. during early tobacco exposure), perhaps helping to explain differential vulnerability to nicotine dependence. This study explored associations of functional candidate gene polymorphisms with initial sensitivity to nicotine in 101 young adult nonsmokers of European ancestry. Nicotine (0, 5, 10 microg/kg) was administered through nasal spray followed by mood, nicotine reward (e.g. 'liking') and perception (e.g. 'feel effects') measures, physiological responses, sensory processing (prepulse inhibition of startle), and performance tasks. Nicotine reinforcement was assessed in a separate session using a nicotine versus placebo spray choice procedure. For the dopamine D4 receptor [DRD4 variable number of tandem repeats (VNTR)], presence of the 7-repeat allele was associated with greater aversive responses to nicotine (decreases in 'vigor', positive affect, and rapid information processing; increased cortisol) and reduced nicotine choice. Individuals with at least one DRD4 7-repeat allele also reported increased 'feel effects' and greater startle response, but in men only. Other genetic associations were also observed in men but not women, such as greater 'feel effects' and anger, and reduced fatigue, in the dopamine D2 receptor (DRD2 C957T single nucleotide polymorphism) TT versus CT or CC genotypes. Very few or no significant associations were seen for the DRD2/ANKK1 TaqIA polymorphism, the serotonin transporter promoter VNTR or 5HTTLPR (SLC6A4), the dopamine transporter 3' VNTR (SLC6A3), and the mu opioid receptor A118G single nucleotide polymorphism (mu opioid receptor polymorphism 1). Although these results are preliminary, this study is the first to suggest that genetic polymorphisms related to function in the dopamine D4, and perhaps D2, receptor may modulate initial sensitivity to nicotine before the onset of dependence and may do so differentially between men and women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690117      PMCID: PMC2743299          DOI: 10.1097/FBP.0b013e32830c3621

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  55 in total

Review 1.  Initial tobacco use episodes in children and adolescents: current knowledge, future directions.

Authors:  T Eissenberg; R L Balster
Journal:  Drug Alcohol Depend       Date:  2000-05-01       Impact factor: 4.492

2.  Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.

Authors:  Caryn Lerman; Christopher Jepson; E Paul Wileyto; Leonard H Epstein; Margaret Rukstalis; Freda Patterson; Vyga Kaufmann; Stephanie Restine; Larry Hawk; Ray Niaura; Wade Berrettini
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

Review 3.  Genetics and smoking cessation improving outcomes in smokers at risk.

Authors:  Caryn E Lerman; Robert A Schnoll; Marcus R Munafò
Journal:  Am J Prev Med       Date:  2007-12       Impact factor: 5.043

4.  Importance of environmental distractors in the effects of nicotine on short-term memory.

Authors:  J E Grobe; K A Perkins; J Goettler-Good; A Wilson
Journal:  Exp Clin Psychopharmacol       Date:  1998-05       Impact factor: 3.157

Review 5.  Does nicotine do what we think it does? A meta-analytic review of the subjective effects of nicotine in nasal spray and intravenous studies with smokers and nonsmokers.

Authors:  David Kalman; Stevens S Smith
Journal:  Nicotine Tob Res       Date:  2005-06       Impact factor: 4.244

Review 6.  Nicotine discrimination in men and women.

Authors:  K A Perkins
Journal:  Pharmacol Biochem Behav       Date:  1999-10       Impact factor: 3.533

7.  C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo.

Authors:  M Hirvonen; A Laakso; K Någren; J O Rinne; T Pohjalainen; J Hietala
Journal:  Mol Psychiatry       Date:  2004-12       Impact factor: 15.992

8.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.

Authors:  Jubao Duan; Mark S Wainwright; Josep M Comeron; Naruya Saitou; Alan R Sanders; Joel Gelernter; Pablo V Gejman
Journal:  Hum Mol Genet       Date:  2003-02-01       Impact factor: 6.150

9.  Interacting effects of genetic predisposition and depression on adolescent smoking progression.

Authors:  Janet Audrain-McGovern; Caryn Lerman; E Paul Wileyto; Daniel Rodriguez; Peter G Shields
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

Review 10.  Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence.

Authors:  O F Pomerleau
Journal:  Behav Genet       Date:  1995-03       Impact factor: 2.805

View more
  19 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

Review 2.  Nicotine reduction revisited: science and future directions.

Authors:  Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller
Journal:  Tob Control       Date:  2010-10       Impact factor: 7.552

Review 3.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

4.  Associations Between Initial Subjective Experiences with Tobacco and Self-Reported Recent Use in Young Adulthood.

Authors:  Elizabeth K Do; Elizabeth C Prom-Wormley; Bernard F Fuemmeler; Danielle M Dick; Kenneth S Kendler; Hermine H Maes
Journal:  Subst Use Misuse       Date:  2018-05-29       Impact factor: 2.164

5.  Dopamine polymorphisms and depressive symptoms predict foods intake. Results from a nationally representative sample.

Authors:  Tanya Agurs-Collins; Bernard F Fuemmeler
Journal:  Appetite       Date:  2011-06-06       Impact factor: 3.868

Review 6.  Adolescent brain maturation and smoking: what we know and where we're headed.

Authors:  David M Lydon; Stephen J Wilson; Amanda Child; Charles F Geier
Journal:  Neurosci Biobehav Rev       Date:  2014-07-12       Impact factor: 8.989

7.  Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerström test for nicotine dependence.

Authors:  Jennifer Wessel; Sarah M McDonald; David A Hinds; Renee P Stokowski; Harold S Javitz; Michael Kennemer; Ruth Krasnow; William Dirks; Jill Hardin; Steven J Pitts; Martha Michel; Lisa Jack; Dennis G Ballinger; Jennifer B McClure; Gary E Swan; Andrew W Bergen
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

8.  Empirical support for a multi-dimensional model of sensations experienced by youth during their initial smoking episodes.

Authors:  Chris G Richardson; Chizimuzo T C Okoli; Pamela A Ratner; Joy L Johnson
Journal:  Addiction       Date:  2010-08-16       Impact factor: 6.526

9.  The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism.

Authors:  Nadine Petrovsky; Ulrich Ettinger; Henrik Kessler; Rainald Mössner; Steffen Wolfsgruber; Norbert Dahmen; Wolfgang Maier; Michael Wagner; Boris B Quednow
Journal:  Psychopharmacology (Berl)       Date:  2013-04-19       Impact factor: 4.530

10.  Substance use, trait measures, and subjective response to nicotine in never-smokers stratified on parental smoking history and sex.

Authors:  Ovide F Pomerleau; Cynthia S Pomerleau; Sandy M Snedecor; Raphaela Finkenauer; Ann M Mehringer; Scott A Langenecker; Erik J Sirevaag
Journal:  Nicotine Tob Res       Date:  2009-07-24       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.